
Eli Lilly and Company LLY
Annual report 2025
added 02-12-2026
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
897 M |
Market Cap[1] |
$ 886 B |
EBITDA (LTM) |
$ 2.37 B |
P/E (LTM) |
71.25 |
P/S (LTM) |
17.21 |
EPS (LTM) |
13.74 |
Eli Lilly and Company is one of the world's largest pharmaceutical companies, specializing in the development, manufacturing, and sale of innovative drugs for the treatment of various diseases.
The company was founded in 1876 in Indianapolis, Indiana and has since become a leader in the pharmaceutical industry. Eli Lilly and Company develops and manufactures a wide range of drugs, including those for diabetes, cancer, mental disorders, Alzheimer's disease, and other illnesses.
One of the company's most well-known developments is insulin, which was created in 1923. This drug became the first effective treatment for diabetes and has saved millions of lives worldwide.
Eli Lilly and Company actively invests in research and development of new drugs to help patients worldwide fight various diseases. The company also aims to improve the quality of life for patients by providing them with access to high-quality drugs. Is a global company with operations in more than 125 countries. The company cares about its employees and society as a whole, participating in various charitable projects and social responsibility programs.
Overall, is one of the most successful and innovative companies in the pharmaceutical industry. Its products help millions of people worldwide overcome difficulties associated with various diseases and improve their quality of life.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
AbCellera Biologics
ABCL
|
$ 3.44 | -4.32 % | $ 1.03 B | Nasdaq Global Select Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Aptorum Group Limited
APM
|
$ 0.79 | -1.15 % | $ 4.31 M | Nasdaq Global Select Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
ADMA Biologics
ADMA
|
$ 15.36 | -2.17 % | $ 3.66 B | Nasdaq Global Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Apellis Pharmaceuticals
APLS
|
$ 20.28 | 0.65 % | $ 2.56 B | Nasdaq Global Select Market,SPB | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.51 | 1.35 % | $ 385 M | Nasdaq Global Select Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Anika Therapeutics
ANIK
|
$ 14.05 | -1.44 % | $ 206 M | Nasdaq Global Select Market,SPB | ||
|
ANI Pharmaceuticals
ANIP
|
$ 74.36 | -1.64 % | $ 1.44 B | Nasdaq Global Market,SPB | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | Nasdaq Capital Market | ||
|
Axsome Therapeutics
AXSM
|
$ 162.43 | 0.6 % | $ 8.08 B | Nasdaq Global Market,SPB | ||
|
BioCryst Pharmaceuticals
BCRX
|
$ 8.49 | -0.18 % | $ 1.75 B | Nasdaq Global Select Market | ||
|
BridgeBio Pharma
BBIO
|
$ 65.66 | -0.78 % | $ 12.6 B | Nasdaq Global Select Market,SPB | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | ||
|
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | ||
|
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
BioLineRx Ltd.
BLRX
|
$ 2.69 | -0.74 % | $ 908 M | Nasdaq Capital Market | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 61.3 | 1.21 % | $ 11.8 B | Nasdaq Global Select Market,SPB | ||
|
Burford Capital Limited
BUR
|
$ 7.79 | -5.75 % | $ 1.28 B | NYSE | ||
|
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | ||
|
Codexis
CDXS
|
$ 1.23 | -2.38 % | $ 90.3 M | Nasdaq Global Select Market | ||
|
Cabaletta Bio
CABA
|
$ 3.18 | -0.16 % | $ 3.71 M | Nasdaq Global Select Market | ||
|
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | ||
|
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.